Hi-Tech acquires Midlothian’s assets
This article was originally published in The Tan Sheet
Amityville, N.Y.-based Hi-Tech Pharmacal signed an agreement Dec. 31 to acquire the assets of Midlothian Laboratories for $5 million, the firm says. Additionally, Hi-Tech will pay almost $1 million for inventory and potentially up to $1 million in performance incentives tied to future Midlothian product sales and abbreviated new drug application approval. Hi-Tech will receive rights to Midlothian's portfolio of prescription nutritional supplements as well as future ANDA and non-ANDA products in development. According to Hi-Tech, Midlothian had sales of approximately $5.6 million and pre-tax income of $800,000 in 2006...
You may also be interested in...
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.